Latest & greatest articles for rivaroxaban

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rivaroxaban or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rivaroxaban and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rivaroxaban

81. Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations. (PubMed)

Evaluating Rivaroxaban for Nonvalvular Atrial Fibrillation - Regulatory Considerations. 21992495 2011 11 23 2015 11 19 1533-4406 365 17 2011 Oct 27 The New England journal of medicine N. Engl. J. Med. Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. 1557-9 10.1056/NEJMp1110639 Fleming Thomas R TR Department of Biostatistics, University of Washington, Seattle, USA. Emerson Scott S SS eng Journal Article 2011 10 05 United States N Engl J Med 0255562 0028-4793 (...) 0 Anticoagulants 0 Morpholines 0 Thiophenes 9NDF7JZ4M3 Rivaroxaban AIM IM Advisory Committees Anticoagulants therapeutic use Atrial Fibrillation drug therapy Clinical Trials as Topic Drug Approval legislation & jurisprudence Government Regulation Humans Morpholines therapeutic use Rivaroxaban Thiophenes therapeutic use United States United States Food and Drug Administration 2011 10 14 6 0 2011 10 14 6 0 2011 12 13 0 0 ppublish 21992495 10.1056/NEJMp1110639

2011 NEJM

82. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery

Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery (...) Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ringerike T, Hamidi V, Hagen G, Reikvam A, Klemp M. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Oslo: Norwegian Knowledge Centre

2011 Health Technology Assessment (HTA) Database.

83. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]

[Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L (...) . Dabigatran y rivaroxaban como tromboprofilaxis luego de una cirugia ortopedica mayor. [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No 41. 2011 Authors' objectives To assess the available evidence on the efficacy, safety and other issues related with coverage policies on the use of dabigatran and rivaroxaban as thrombophylaxis after a major orthopedic surgery. Authors

2011 Health Technology Assessment (HTA) Database.

84. Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison

Dabigatran and rivaroxaban for prevention of venous thromboembolism: systematic review and adjusted indirect comparison Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

85. Xarelto (Rivaroxaban)

Xarelto (Rivaroxaban) Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xarelto (Rivaroxaban) NDA 202439 Company: Janssen Pharmaceuticals Application No.: 202439 Approval Date: 11/04/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

86. Xarelto (rivaroxaban)

Xarelto (rivaroxaban) Drug Approval Package: Xarelto (rivaroxaban) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Xarelto (rivaroxaban) 10 mg immediate release Tablets Company: Johnson and Johnson Pharmaceutical Research and Development, LLC Application No.: 022406 Approval Date: 07/01/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

87. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. (PubMed)

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (...) (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism.In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 for noninferiority

Full Text available with Trip Pro

2011 NEJM

88. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong (...) L, Lees M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after surgery in patients undergoing total hip or knee

2011 NHS Economic Evaluation Database.

89. Randomised controlled trial: Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications

Randomised controlled trial: Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications Article Text Therapeutics Randomised controlled trial Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications David J Rosenberg 1 , Jack Ansell 2 Statistics from

2011 Evidence-Based Medicine (Requires free registration)

90. Oral rivaroxaban for symptomatic venous thromboembolism. (PubMed)

Oral rivaroxaban for symptomatic venous thromboembolism. Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (...) (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding

Full Text available with Trip Pro

2010 NEJM

91. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

92. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement (PubMed)

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme). A pooled analysis of data from these studies (n = 9581) showed that rivaroxaban was more effective than (...) %). Rivaroxaban started six to eight hours after surgery was more effective than enoxaparin started the previous evening in preventing symptomatic venous thromboembolism and all-cause mortality, without increasing major bleeding.

Full Text available with Trip Pro

2009 EvidenceUpdates

93. Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement

Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement Home - Monash Health Find a Location Latest news Victorian Minister for Health Jenny Mikakos MP meets a patient and researcher leading the world-first safety trial examining stem cells as therapy for acute stroke. Your health Heat kills more people than any natural disaster. Be prepared and survive the heat this summer. Our children’s hospital Monash Children’s Hospital is one of Australia’s

2009 Monash Health Evidence Reviews

94. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. (PubMed)

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could enable shorter hospital stays. We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty.In a randomised, double-blind, phase III study, 3148 patients undergoing knee arthroplasty (...) received either oral rivaroxaban 10 mg once daily, beginning 6-8 h after surgery, or subcutaneous enoxaparin 30 mg every 12 h, starting 12-24 h after surgery. Patients had mandatory bilateral venography between days 11 and 15. The primary efficacy outcome was the composite of any deep-vein thrombosis, non-fatal pulmonary embolism, or death from any cause up to day 17 after surgery. Efficacy was assessed as non-inferiority of rivaroxaban compared with enoxaparin in the per-protocol population (absolute

2009 Lancet

95. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. (PubMed)

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in prevention of venous thromboembolism in patients undergoing elective orthopaedic surgery. However, its use after acute coronary syndromes has not been investigated. In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing (...) regimen.In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730). Participants were randomised within each strata and dose tier with a block randomisation method at 1:1:1 to receive either placebo or rivaroxaban (at doses 5-20 mg) given once daily or the same total

2009 Lancet

96. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technology Assessment 2009; 13(Suppl 3 Article 7): 43-48 Final publication URL PubMedID Additional data URL Indexing Status Subject indexing assigned by NLM MeSH Adult; Anticoagulants /economics /therapeutic use; Arthroplasty, Replacement, Hip /adverse effects; Arthroplasty, Replacement, Knee /adverse effects; Cost-Benefit

Full Text available with Trip Pro

2009 Health Technology Assessment (HTA) Database.

97. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 170. 2009 Authors' conclusions Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip

2009 Health Technology Assessment (HTA) Database.

98. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

2009 Health Technology Assessment (HTA) Database.

99. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium (...) as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting McCullagh L, Tilson L, Walsh C, Barry M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rivaroxaban

2009 NHS Economic Evaluation Database.

100. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170) Overview | Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | Guidance | NICE Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Technology appraisal guidance [TA170] Published date: 22 April 2009 Share Guidance on rivaroxaban (Xarelto) for preventing venous

2009 National Institute for Health and Clinical Excellence - Technology Appraisals